Source-grounded facts extracted from BRISTOL MYERS SQUIBB CO's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BRISTOL MYERS SQUIBB CO shareholders rejected Adoption of a board policy that the chairperson of the board be an independent director at the 2026-05-05 meeting.
“The shareholder proposal on the adoption of a board policy that the chairperson of the board be an independent director was not approved based upon the following votes: For Against Abstain Broker Non-Vote 422,069,323 1,109,378,680 7,137,394 234,927,659”
BRISTOL MYERS SQUIBB CO shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026 at the 2026-05-05 meeting.
“The appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for 2026 was ratified based upon the following votes: For Against Abstain 1,706,279,839 63,727,901 3,505,316”
BRISTOL MYERS SQUIBB CO shareholders approved Approval of the Company's 2026 stock award and incentive plan at the 2026-05-05 meeting.
“The management proposal on the vote to approve the Company’s 2026 stock award and incentive plan was approved based upon the following votes: For Against Abstain Broker Non-Vote 1,470,672,957 63,896,918 4,015,522 234,927,659”
BRISTOL MYERS SQUIBB CO shareholders approved Advisory vote to approve the compensation of our named executive officers at the 2026-05-05 meeting.
“The management proposal on the advisory vote to approve the compensation of our named executive officers was approved based upon the following votes: For Against Abstain Broker Non-Vote 1,459,162,310 72,490,026 6,933,061 234,927,659”
BRISTOL MYERS SQUIBB CO shareholders approved Election of Directors at the 2026-05-05 meeting.
“The shareholders elected each of the Company’s 11 nominees to serve as directors of the Company until the 2027 Annual Meeting based upon the following votes: For Against Abstain Broker Non-Vote Peter J. Arduini 1,489,115,718 46,952,408 2,517,271 234,927,659 Deepak L. Bhatt, M.D., M.P.H., M.B.A. 1,519,336,832 16,821,065 2,427,500 234,927,659 Christopher S. Boerner, Ph.D. 1,462,672,450 73,500,542 2,412,405 234,927,659 Julia A. Haller, M.D. 1,513,280,188 23,027,628 2,277,581 234,927,659 Manuel Hidalgo Medina, M.D., Ph.D. 1,513,107,431 23,055,022 2,422,944 234,927,659 Michael R. McMullen 1,520,590,126 15,506,431 2,488,840 234,927,659 Paula A. Price 1,506,560,939 29,652,099 2,372,359 234,927,659 Derica W. Rice 1,493,345,909 42,806,350 2,433,138 234,927,659 Theodore R. Samuels 1,487,884,432 48,111,146 2,589,819 234,927,659 Karen H. Vousden, Ph.D. 1,519,199,326 17,078,052 2,308,019 234,927,659 Phyllis R. Yale 1,527,736,604 8,485,885 2,362,908 234,927,659”
BRISTOL MYERS SQUIBB CO reported the first quarter of 2026 results: revenue $11,489, EPS $1.31. Guidance reaffirmed.
“progress into meaningful outcomes for patients and shareholders." First Quarter Results $ in millions, except per share amounts 2026 2025 Change Change Excl. FX** Total Revenues $11,489 $11,201 3 % 1 % Earnings/(Loss) Per Share - GAAP* 1.31 1.20 9 % N/A Earnings/(Loss) Per Share - Non-GAAP* 1.58 1.80 (12) % N/A Acquired IPRD Charges and Licensing Income Net”
Sandra Leung retired as Executive Vice President, General Counsel at BRISTOL MYERS SQUIBB CO.
“On February 14 , 2025, Sandra Leung notified Bristol-Myers Squibb Company (the “Company”) of her intention to retire from her position as Executive Vice President, General Counsel in 2025.”
Michael R. McMullen was elected as Director at BRISTOL MYERS SQUIBB CO.
“On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.”
BRISTOL MYERS SQUIBB CO shareholders rejected Shareholder proposal on Executive Retention of Significant Stock at the 2024-05-07 meeting.
“Item 6. The shareholder proposal on Executive Retention of Significant Stock was not approved based upon the following votes: For Against Abstain Broker Non-Vote 573,933,418 908,578,794 7,210,637 266,572,438”
BRISTOL MYERS SQUIBB CO shareholders rejected Shareholder proposal on adoption of Board policy that Chairperson be independent director at the 2024-05-07 meeting.
“Item 5. The shareholder proposal on the adoption of a Board policy that the Chairperson of the Board be an independent director was not approved based upon the following votes: For Against Abstain Broker Non-Vote 472,322,369 1,011,335,836 6,064,644 266,572,438”
BRISTOL MYERS SQUIBB CO shareholders approved Approval of amendment to Amended and Restated Certificate of Incorporation to eliminate or limit monetary liability of specified executive officers for breach of duty of care at the 2024-05-07 meeting.
“Item 4. The management proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to provide for the elimination or limitation of monetary liability of specified executive officers of the Company for breach of the duty of care was approved by a majority of the outstanding shares (the required voting standard for this proposal) based upon the following votes: For Against Abstain Broker Non-Vote 1,256,661,971 227,187,844 5,873,034 266,572,438”
BRISTOL MYERS SQUIBB CO shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2024 at the 2024-05-07 meeting.
“Item 3. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for 2024 was ratified based upon the following votes: For Against Abstain 1,706,412,572 45,388,759 4,493,956”
BRISTOL MYERS SQUIBB CO shareholders approved Advisory vote to approve compensation of named executive officers at the 2024-05-07 meeting.
“Item 2. The management proposal on the advisory vote to approve the compensation of our named executive officers was approved based upon the following votes: For Against Abstain Broker Non-Vote 1,398,917,461 82,961,647 7,843,741 266,572,438”
BRISTOL MYERS SQUIBB CO shareholders approved Election of 10 director nominees at the 2024-05-07 meeting.
“Item 1. The shareholders elected each of the Company’s 10 nominees to serve as directors on the Board of Directors (the “Board”) of the Company until the 2025 Annual Meeting based upon the following votes: For Against Abstain Broker Non-Vote Peter J. Arduini 1,383,602,367 102,481,962 3,638,520 266,572,438 Deepak L. Bhatt, M.D., M.P.H. 1,476,515,465 9,708,358 3,499,026 266,572,438 Christopher S. Boerner, Ph.D. 1,384,853,031 94,529,721 10,340,097 266,572,438 Julia A. Haller, M.D. 1,476,206,049 10,127,433 3,389,367 266,572,438 Manuel Hidalgo Medina, M.D., Ph.D. 1,476,575,465 9,619,439 3,527,945 266,572,438 Paula A. Price 1,454,211,368 32,151,447 3,360,034 266,572,438 Derica W. Rice 1,434,633,116 51,626,067 3,463,666 266,572,438 Theodore R. Samuels 1,424,280,995 61,627,002 3,814,852 266,572,438 Karen H. Vousden, Ph.D. 1,453,794,945 32,477,142 3,450,762 266,572,438 Phyllis R. Yale 1,466,891,645 19,409,908 3,421,296 266,572,438”
BRISTOL MYERS SQUIBB CO reported the first quarter of 2024 results: revenue $11,865, EPS (5.89).
“get the most promising medicines to patients as quickly as possible." 1 First Quarter $ in millions, except per share amounts 2024 2023 Change Change Excl. F/X** Total Revenues $11,865 $11,337 5 % 6 % (Loss)/Earnings Per Share — GAAP* (5.89) 1.07 N/A N/A (Loss)/Earnings Per Share — Non-GAAP* ** (4.40) 2.05 N/A N/A Acquired IPRD charge and Licensing Income Net”
Gerald Storch departed as Director at BRISTOL MYERS SQUIBB CO.
“On March 13, 2024, Mr. Gerald Storch notified the Board of Directors (the "Board") of Bristol-Myers Squibb Company (the "Company") that he will not stand for re-election to the Board of the Company at the 2024 Annual Meeting of Shareholders.”
Sharon Greenlees changed role as Senior Vice President and Controller at BRISTOL MYERS SQUIBB CO.
“Ms. Sharon Greenlees, Senior Vice President and Controller, will assume another role at the Company, effective February 15, 2024.”
Phil Holzer was appointed as Senior Vice President and Controller at BRISTOL MYERS SQUIBB CO.
“Effective February 15, 2024, Mr. Phil Holzer will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company”
BRISTOL MYERS SQUIBB CO reported full year of 2023 results: revenue $45,006, EPS GAAP EPS of $3.86 and Non-GAAP EPS of $7.51. Guidance initiated.
“1 Fourth Quarter Full Year $ in millions, except per share amounts 2023 2022 Change Change Excl. F/X** 2023 2022 Change Change Excl. F/X** Total Revenues $11,477 $11,406 1 % 1 % $45,006 $46,159 (2) % (2) % EPS — GAAP* 0.87 0.95 (8) % N/A 3.86 2.95 31 % N/A EPS — Non-GAAP* 1.70 1.82 (7) % N/A 7.51 7.70 (2) % N/A Acquired IPRD charge and Licensing Income Net Impact”
BRISTOL MYERS SQUIBB CO reported the fourth quarter of 2023 results: revenue $11,477, EPS GAAP EPS of $0.87 and Non-GAAP EPS of $1.70.
“the decade and beyond." 1 Fourth Quarter Full Year $ in millions, except per share amounts 2023 2022 Change Change Excl. F/X** 2023 2022 Change Change Excl. F/X** Total Revenues $11,477 $11,406 1 % 1 % $45,006 $46,159 (2) % (2) % EPS — GAAP* 0.87 0.95 (8) % N/A 3.86 2.95 31 % N/A EPS — Non-GAAP* 1.70 1.82 (7) % N/A 7.51 7.70 (2) % N/A Acquired IPRD charge and”
Christopher Boerner was appointed as Chairman of the Board at BRISTOL MYERS SQUIBB CO.
“the Board approved the appointment of Dr. Boerner as Chairman of the Board in addition to Chief Executive Officer, effective April 1, 2024”
Christopher Boerner was appointed as Chief Executive Officer at BRISTOL MYERS SQUIBB CO.
“appointment of Christopher Boerner, Ph.D. as Chief Executive Officer by the Board, effective November 1, 2023”
Giovanni Caforio departed as Director at BRISTOL MYERS SQUIBB CO.
“On October 25, 2023, Dr. Caforio advised the Board that he will not stand for re-election to the Board at the 2024 Annual Meeting of Shareholders, and will retire from the Board, effective April 1, 2024.”
Giovanni Caforio was appointed as Executive Chairman at BRISTOL MYERS SQUIBB CO.
“retirement of Giovanni Caforio, M.D. as Chief Executive Officer and his election as Executive Chairman of the Board of Directors of the Company (the “Board”), effective November 1, 2023”
BRISTOL MYERS SQUIBB CO reported the third quarter of 2023 results: revenue $10,966, EPS 0.93.
“business development opportunities that benefit patients." 1 Third Quarter $ amounts in millions, except per share amounts 2023 2022 Change Change Excl. F/X** Total Revenues $10,966 $11,218 (2) % (3) % Earnings per share - GAAP* 0.93 0.75 24 % N/A Earnings per share - Non-GAAP* 2.00 1.99 1 % N/A * GAAP and Non-GAAP earnings per share include the net impact of”
BRISTOL MYERS SQUIBB CO reported the second quarter of 2023 results: revenue $11.2 Billion, EPS $0.99. Guidance lowered.
“Bristol Myers Squibb Reports Second Quarter Financial Results for 2023 • Reports Second Quarter Revenues of $11.2 Billion • Posts Second Quarter GAAP Earnings Per Share of $0.99 and Non-GAAP EPS of $1.75;”
BRISTOL MYERS SQUIBB CO shareholders rejected Shareholder proposal on special shareholder meeting improvement at the 2023-05-02 meeting.
“Item 7. The shareholder proposal on special shareholder meeting improvement was not approved based upon the following votes: Broker For Against Abstain Non-Vote 90,237,608 1,448,468,707 24,553,339 268,683,382”
BRISTOL MYERS SQUIBB CO shareholders rejected Shareholder proposal on workplace non-discrimination audit at the 2023-05-02 meeting.
“Item 6. The shareholder proposal on workplace non-discrimination audit was not approved based upon the following votes: Broker For Against Abstain Non-Vote 23,891,859 1,503,971,016 35,396,779 268,683,382”
BRISTOL MYERS SQUIBB CO shareholders rejected Shareholder proposal on the adoption of a Board policy that the Chairperson of the Board be an independent director at the 2023-05-02 meeting.
“Item 5. The shareholder proposal on the adoption of a Board policy that the Chairperson of the Board be an independent director was not approved based upon the following votes: Broker For Against Abstain Non-Vote 495,551,854 1,061,784,252 5,923,548 268,683,382”
BRISTOL MYERS SQUIBB CO shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2023 at the 2023-05-02 meeting.
“Item 4. The appointment of Deloitte & Touche LLP as independent registered public accounting firm for the Company for 2023 was ratified based upon the following votes: For Against Abstain 1,772,411,521 55,636,602 3,894,913”
BRISTOL MYERS SQUIBB CO shareholders approved Advisory vote on the frequency of the advisory vote to approve compensation of named executive officers at the 2023-05-02 meeting.
“Item 3. The management proposal on the advisory vote of the frequency of the advisory vote to approve the compensation of our named executive officers was approved for one year based upon the following votes: One Year Two Years Three Years Abstain Broker Non-Vote 1,525,837,873 4,106,448 28,850,524 4,464,809 268,683,382”
BRISTOL MYERS SQUIBB CO shareholders approved Advisory vote to approve the compensation of named executive officers at the 2023-05-02 meeting.
“Item 2. The management proposal on the advisory vote to approve the compensation of our named executive officers was approved based upon the following votes: Broker For Against Abstain Non-Vote 1,438,045,960 118,332,598 6,881,096 268,683,382”
BRISTOL MYERS SQUIBB CO shareholders approved Election of 11 nominees to serve as directors until the 2024 Annual Meeting at the 2023-05-02 meeting.
“Item 1. The shareholders elected each of the Company’s 11 nominees to serve as directors of the Company until the 2024 Annual Meeting based upon the following votes: For Against Abstain Broker Non-Vote Peter J. Arduini 1,513,964,261 45,262,343 4,033,050 268,683,382 Deepak L. Bhatt, M.D., M.P.H. 1,549,329,749 9,930,821 3,999,084 268,683,382 Giovanni Caforio, M.D. 1,435,621,163 118,279,157 9,359,334 268,683,382 Julia A. Haller, M.D. 1,535,005,342 25,501,075 2,753,237 268,683,382 Manuel Hidalgo Medina, M.D., Ph.D. 1,533,923,291 25,393,637 3,942,726 268,683,382 Paula A. Price 1,517,082,822 42,393,024 3,783,808 268,683,382 Derica W. Rice 1,487,320,744 71,913,805 4,025,105 268,683,382 Theodore R. Samuels 1,479,191,052 80,861,588 3,207,014 268,683,382 Gerald L. Storch 1,445,066,253 114,101,188 4,092,213 268,683,382 Karen H. Vousden, Ph.D. 1,517,425,805 42,124,841 3,709,008 268,683,382 Phyllis R. Yale 1,529,099,472 30,340,910 3,819,272 268,683,382”
Christopher Boerner was elected as Director at BRISTOL MYERS SQUIBB CO.
“the Board elected Dr. Boerner, to serve as a member of the Board, effective May 2, 2023”
Christopher Boerner was appointed as Chief Executive Officer at BRISTOL MYERS SQUIBB CO.
“and as the Chief Executive Officer, effective November 1, 2023”
Christopher Boerner was appointed as Chief Operating Officer at BRISTOL MYERS SQUIBB CO.
“appointed Christopher Boerner, Ph.D., to serve as the Company’s Chief Operating Officer, effective April 26, 2023”
BRISTOL MYERS SQUIBB CO reported first quarter of 2023 results: revenue $11.3 Billion, EPS GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05. Guidance reaffirmed.
“Reports First Quarter Revenues of $11.3 Billion • Posts First Quarter GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05”
Christopher Boerner was appointed as Chief Executive Officer at BRISTOL MYERS SQUIBB CO.
“the Board appointed Christopher Boerner, Ph.D., to serve as the Company’s Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023.”
Christopher Boerner was appointed as Chief Operating Officer at BRISTOL MYERS SQUIBB CO.
“the Board appointed Christopher Boerner, Ph.D., to serve as the Company’s Chief Operating Officer, effective April 26, 2023, and as the Chief Executive Officer, effective November 1, 2023.”
Giovanni Caforio retired as Chairman of the Board and Chief Executive Officer at BRISTOL MYERS SQUIBB CO.
“Giovanni Caforio, M.D., the Company’s Chairman of the Board of Directors (“Board”) and Chief Executive Officer, has decided to retire as Chief Executive Officer (“CEO”) effective November 1, 2023.”
BRISTOL MYERS SQUIBB CO updated its 2023 guidance (initiated).
“• Provides GAAP and Non-GAAP Financial Guidance for 2023 Reflecting Continued Revenue and Earnings Growth”
BRISTOL MYERS SQUIBB CO reported full year of 2022 results: revenue $46.2 Billion, EPS $2.95.
“• Reports Fourth Quarter Revenues of $11.4 Billion; Full-Year Revenues of $46.2 Billion ◦ Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted for Foreign Exchange ◦ Full-Year Revenues from In-Line Products and New Product Portfolio were $35.4 Billion, an Increase of 9%, or 13% When Adjusted for Foreign Exchange • Posts Fourth Quarter GAAP EPS of $0.95 and Non-GAAP EPS of $1.82; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income • Reports Full-Year GAAP EPS of $2.95 and Non-GAAP EPS of $7.70; Includes Net Impact of ($0.24) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income”
BRISTOL MYERS SQUIBB CO reported the fourth quarter of 2022 results: revenue $11.4 Billion, EPS $0.95.
“• Reports Fourth Quarter Revenues of $11.4 Billion; Full-Year Revenues of $46.2 Billion ◦ Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted for Foreign Exchange ◦ Full-Year Revenues from In-Line Products and New Product Portfolio were $35.4 Billion, an Increase of 9%, or 13% When Adjusted for Foreign Exchange • Posts Fourth Quarter GAAP EPS of $0.95 and Non-GAAP EPS of $1.82; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income”
Rupert Vessey resigned as Executive Vice President, Research and Early Development at BRISTOL MYERS SQUIBB CO.
“Effective July 3, 2023, Dr. Rupert Vessey, Executive Vice President, Research and Early Development, has decided to leave Bristol-Myers Squibb Company (the “Company”).”
Deepak L. Bhatt was elected as Director at BRISTOL MYERS SQUIBB CO.
“On June 14, 2022, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Deepak L. Bhatt , M.D., M.P.H., to serve as a member of the Board, effective June 14, 2022.”
Karen Murphy Santiago departed as Senior Vice President and Controller at BRISTOL MYERS SQUIBB CO.
“Ms. Karen Murphy Santiago, Senior Vice President and Controller, will leave the Company by May 1, 2022.”
Sharon Greenlees was appointed as Senior Vice President and Controller at BRISTOL MYERS SQUIBB CO.
“Effective April 25, 2022, Ms. Sharon Greenlees will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company (the “Company”).”
Michael Bonney resigned as Director at BRISTOL MYERS SQUIBB CO.
“On August 3, 2021, Mr. Michael Bonney resigned from the Board of Directors of Bristol-Myers Squibb Company in connection with his appointment as Executive Chairman of Alnylam Pharmaceuticals Inc .”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.